Molcure Inc., a biotechnology firm specializing in artificial intelligence-based drug discovery, has entered into a multi-year strategic research agreement with Boehringer Ingelheim focused on the development of antibody therapeutics targeting multiple disease areas, leveraging Molcure’s proprietary AI platform. The collaboration is designed to combine Molcure’s expertise in AI-driven antibody engineering with Boehringer Ingelheim’s capabilities in high-throughput experimentation. Molcure’s p...